Latest news with #Gerberry
Business Insider
6 days ago
- Business
- Business Insider
Bank of America Securities Sticks to Its Buy Rating for Liquidia Technologies (LQDA)
Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Liquidia Technologies yesterday and set a price target of $35.00. The company's shares closed yesterday at $24.10. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Gerberry covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, Liquidia Technologies, and BioMarin Pharmaceutical. According to TipRanks, Gerberry has an average return of 2.5% and a 48.57% success rate on recommended stocks. In addition to Bank of America Securities, Liquidia Technologies also received a Buy from LifeSci Capital's Cory Jubinville, PhD in a report issued yesterday. However, on July 29, Oppenheimer maintained a Sell rating on Liquidia Technologies (NASDAQ: LQDA). Based on Liquidia Technologies' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $3.12 million and a GAAP net loss of $38.37 million. In comparison, last year the company earned a revenue of $2.97 million and had a GAAP net loss of $40.93 million
Business Insider
6 days ago
- Business
- Business Insider
Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), Oric Pharmaceuticals (ORIC) and Insmed (INSM)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ProKidney (PROK – Research Report), Oric Pharmaceuticals (ORIC – Research Report) and Insmed (INSM – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. ProKidney (PROK) In a report released yesterday, Jason Gerberry from Bank of America Securities maintained a Sell rating on ProKidney, with a price target of $1.00. The company's shares closed last Tuesday at $2.24. According to Gerberry is a 3-star analyst with an average return of 2.5% and a 48.6% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, BioMarin Pharmaceutical, and Tarsus Pharmaceuticals. ProKidney has an analyst consensus of Moderate Buy, with a price target consensus of $5.60. Oric Pharmaceuticals (ORIC) In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Buy rating on Oric Pharmaceuticals. The company's shares closed last Tuesday at $9.52. According to Rama has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -6.4% and a 39.3% success rate. Rama covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Ultragenyx Pharmaceutical, and Maze Therapeutics, Inc. Oric Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $17.67. Insmed (INSM) In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Insmed. The company's shares closed last Tuesday at $122.00. According to Fye is a 4-star analyst with an average return of 7.7% and a 53.8% success rate. Fye covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Vertex Pharmaceuticals, and Ionis Pharmaceuticals. Insmed has an analyst consensus of Strong Buy, with a price target consensus of $127.94, implying a 13.3% upside from current levels. In a report issued on August 7, Mizuho Securities also maintained a Buy rating on the stock with a $111.26 price target.
